Supplementary Figures 1-9, Supplementary Table 1 from Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib

Zhaohui Wang,Cheng Xu,Bill H. Diplas,Casey J. Moure,Chin-Pu Jason Chen,Lee H. Chen,Changzheng Du,Huishan Zhu,Paula K. Greer,Liwei Zhang,Yiping He,Matthew S. Waitkus,Hai Yan

DOI: https://doi.org/10.1158/1541-7786.22513743

2023-01-01

Abstract:Supplementary Fig. 1. Confirmation of SF7761 derived PPM1D-/- clones by Sanger sequencing. Supplementary Fig. 2. Effect of DNA repair inhibitors on cell viability in SF7761 parental and PPM1D-/- clones. Supplementary Fig. 3. GSK2830371 treatment synergizes with olaparib in PPM1D-mutant DIPG cells. Supplementary Fig. 4. Combination treatment low-dose GSK2830371 and olaparib in TT10714. Supplementary Fig. 5. Matrix plots representation of relative cell viabilities treated with indicated concentrations of olaparib and GSK2830371 for 7 days. Supplementary Fig. 6. 3D spheroid invasion assay performed to assess the growth and invasive potential of TT10714 cells upon single-agent or combination treatments. Supplementary Fig. 7. 3D spheroid invasion assay performed to assess 3D spheroid growth and invasive potential of SF7761 cells upon single-agent or combination treatments. Supplementary Fig. 8. 3D spheroid invasion assay performed to assess 3D spheroid growth and invasive potential of HSJD-DIPG-007 cells upon single-agent or combination treatments. Supplementary Fig. 9. Analysis of 53BP1 foci in response to PPM1D genetic inhibition and olaparib treatment. Supplementary Table 1. Oligos and Primer sequences.